A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia

Publisher： Karger

E-ISSN： 1421-9662|137|2|66-72

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.2, 2016-12, pp. : 66-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 598-601

John Wiley & Sons Inc

Access to resources Recommend Favorite

Usage of Eltrombopag for Chronic Immune Thrombocytopenia as a Pretreatment for Splenectomy

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 45-47

Karger

Access to resources Recommend Favorite

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : E40-E43

John Wiley & Sons Inc

Access to resources Recommend Favorite

United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 590-594

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of eltrombopag after romiplostim in primary immune thrombocytopenia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 111-116

John Wiley & Sons Inc

Access to resources Recommend Favorite